CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.
The New England journal of medicine, 385(18): 1722-1723 PMID 34706181 DOI 10.1056/NEJMc2114592
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.